TRUQAP 160 mg/1

TRUQAP 160 mg is a film-coated tablet containing capivasertib, used for targeted therapy. Learn about its uses, effects, and precautions.

TRUQAP 160 mg is primarily used in targeted therapy for certain types of cancer. Capivasertib, the active ingredient, is designed to inhibit specific proteins involved in cancer cell growth. This medication is often used in combination with other treatments to manage advanced or metastatic cancers. Patients should consult their healthcare provider to determine if TRUQAP 160 mg is suitable for their condition.

Common effects of TRUQAP 160 mg may include fatigue, nausea, and diarrhea. Some patients might experience changes in appetite or skin reactions. These effects can vary widely among individuals, and not everyone will experience them. It's important to monitor any side effects and discuss them with a healthcare professional.

TRUQAP 160 mg should be handled with care, following the prescribed dosage and administration guidelines. It is essential to store the medication properly and keep it out of reach of children. Patients should inform their healthcare provider about any other medications they are taking to avoid potential interactions. Regular follow-ups are recommended to monitor the effectiveness and safety of the treatment.

TRUQAP 160 mg may interact with certain medications, including those that affect liver enzymes. Alcohol and other substances that can cause liver damage should be avoided. Patients should also be cautious with medications that lower the immune system or affect blood clotting. Always consult a healthcare provider before starting or stopping any medication while taking TRUQAP 160 mg.